Amanda Weiss

Amanda Weiss has over 25 years of experience in the biopharmaceutical industry. Amanda started their career in 1996 as the Deputy Director at Cobra Biomanufacturing. In 2006, they moved to Renovo as a Manufacturing Manager. In 2007, they became the Director of Bioprocess Development USP at UCB Pharma. From 2013 to 2016, they held the roles of Head of R&D USP Operations and Head of R&D DSP Operations at Fujifilm Diosynth Biotechnologies. From 2016 to 2019, they were the Validation and Commercial Supply Director at NIGHTSTARX LIMITED. In 2021, they were appointed as the VP CMC at Purespring Therapeutics, a company focused on the kidney globally and advancing gene therapies for the treatment of chronic renal diseases.

Amanda Weiss obtained an MSc in Biochemical Engineering from the University of Birmingham in 1994. Amanda also holds the professional certifications of CEng and FIChemE from the Institute of Chemical Engineers (IChemE).